New drug could slow rare liver disease – major trial underway
NCT ID NCT07387549
First seen Feb 04, 2026 · Last updated May 21, 2026 · Updated 12 times
Summary
This study tests a drug called elafibranor in about 350 adults with primary sclerosing cholangitis (PSC), a rare disease that scars the bile ducts in the liver. The goal is to see if the drug can slow disease progression and improve survival compared to a placebo. Participants will take one tablet daily for several years and have regular check-ups, blood tests, and scans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY SCLEROSING CHOLANGITIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
American Research Corporation at The Texas Liver Institute
RECRUITINGSan Antonio, Texas, 78215, United States
Conditions
Explore the condition pages connected to this study.